


LEGION[◇] posterior stabilised (PS) OXINIUM[◇] Total Knee System (TKS) demonstrates high long-term survivorship with lower revision risk versus other TKA implants in the AOANJRR¹

- Data from the 2024 AOANJRR were obtained via the Automated Industry Report System (AIRS) to compare LEGION PS OXINIUM TKS[†] versus the average for other TKAs when the patella was resurfaced
- This independent analysis includes data from 16,892 LEGION PS OXINIUM TKS[†] procedures collected over >15 years
- Revision risk, expressed as a hazard ratio (HR), has been adjusted for variables such as age and gender

15 years Risk of revision with LEGION PS OXINIUM TKS[†] is **18% lower versus other TKAs** in the AOANJRR when the patella is resurfaced (Adjusted HR: 0.82 [95% CI: 0.75–0.89]; p<0.001)



	0 Yr	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs	6 Yrs	7 Yrs	8 Yrs	9 Yrs	10 Yrs
Number at Risk											
Legion Oxinium PS/Genesis II	16892	15738	14422	13262	12047	11046	9674	8382	6735	4994	3310
Other Total Knee	151110	142883	133802	125559	115427	105880	95029	84048	73042	62244	52683

	11 Yrs	12 Yrs	13 Yrs	14 Yrs	15 Yrs	16 Yrs	17 Yrs	18 Yrs	19 Yrs	20 Yrs	21 Yrs	22 Yrs
Number at Risk												
Legion Oxinium PS/Genesis II	2058	1127	618	301	136	38	2	0	0	0	0	0
Other Total Knee	43834	35755	28153	21636	16237	11706	8021	5210	3337	1887	994	422

Figure 1. Cumulative percentage revision of primary TKA by model (all diagnoses). (Figure 1, AOANJRR AIRS report 28/06/2024)

15 years **94.0% survivorship** for LEGION PS OXINIUM TKS[†] with patella resurfacing

Table 1. Yearly cumulative percent revision of primary TKA by model (all diagnoses). (Table 12, AOANJRR AIRS report 28/06/2024)

CPR	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs
Legion Oxinium PS/Genesis II	0.9 (0.7, 1.0)	1.8 (1.6, 2.0)	2.4 (2.1, 2.6)	2.7 (2.4, 2.9)	3.0 (2.7, 3.3)
Other Total Knee	1.1 (1.0, 1.1)	1.8 (1.8, 1.9)	2.4 (2.3, 2.5)	2.9 (2.8, 2.9)	3.2 (3.1, 3.3)

CPR	6 Yrs	7 Yrs	8 Yrs	9 Yrs	10 Yrs
Legion Oxinium PS/Genesis II	3.2 (3.0, 3.5)	3.4 (3.1, 3.7)	3.7 (3.3, 4.0)	3.8 (3.5, 4.2)	4.2 (3.9, 4.6)
Other Total Knee	3.6 (3.5, 3.7)	3.9 (3.8, 4.0)	4.2 (4.0, 4.3)	4.5 (4.4, 4.6)	4.8 (4.7, 4.9)

CPR	11 Yrs	12 Yrs	13 Yrs	14 Yrs	15 Yrs	16 Yrs
Legion Oxinium PS/Genesis II	4.5 (4.1, 4.9)	4.8 (4.3, 5.3)	5.2 (4.6, 5.9)	5.2 (4.6, 5.9)	6.0 (4.8, 7.3)	
Other Total Knee	5.1 (5.0, 5.3)	5.4 (5.3, 5.6)	5.8 (5.6, 6.0)	6.1 (5.9, 6.3)	6.4 (6.2, 6.6)	6.7 (6.5, 6.9)

CPR	17 Yrs	18 Yrs	19 Yrs	20 Yrs	21 Yrs	22 Yrs
Legion Oxinium PS/Genesis II						
Other Total Knee	7.0 (6.8, 7.2)	7.3 (7.1, 7.6)	7.6 (7.3, 7.9)	8.0 (7.7, 8.5)	8.3 (7.8, 8.8)	8.6 (8.0, 9.2)



Conclusions

At 15 years follow-up, LEGION PS OXINIUM TKS[†] results in high survivorship and lower risk of revision than the average for other TKAs in the AOANJRR (both groups had patella resurfaced).

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use.

[†]LEGION PS OXINIUM (Standard) with GENESIS[®] II baseplate, ODEP Product ID: 9424

Abbreviations: AIRS = automated industry report system; AOANJRR = Australian Orthopaedic Association National Joint Replacement Registry; CI = Confidence Interval; CPR = Cumulative Percent Revision; HR = hazard ratio; PS = posterior stabilised; TKA = total knee arthroplasty; TKS = Total Knee System; yr=year.

References: **1.** Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), Automated Industry Report System (AIRS), ID No.15117[†] for Smith & Nephew Australia, LEGION OXINIUM PS/GENESIS II TKS Report (Procedures from 1 September 1999 – 27 June 2024), Adelaide; AOA, 2024:1–16. Accessed January 12, 2025. **2.** ODEP. Orthopaedic Data Evaluation Panel (ODEP). Available at <http://www.odep.org.uk>. Accessed January 23, 2025.

[‡]AOANJRR is confident in the accuracy of the data included in this report, at the time it was provided. However, it was generated using an automated reporting system and has not been reviewed by the AOANJRR personnel.